Table 2.

Pathologic characteristics of patients with PCA

No. of patients	PCa group (n=94)
Age (years)	63 (54-77)
t-PSA (ng/mL)	12.6 (6.4-42.5)
Prostate volume (cm3)	47.2 (19.1-118.2)
PHI value	57.8 (22.8-256)
PCA3 score	35.6 (14.2-212)
PCA3 score
<15	9 (9.6%)
15-35	15 (16.0%)
35-70	30 (31.9%)
>70	40 (42.5%)
Gleason score
≤7	62 (66.0%)
≥8	32 (34.0%)
% Positive core
<30%	70 (74.5%)
≥30%	24 (25.5%)
Clinical stage
≤III	78 (83.0%)
≥IV	16 (17.0%)

PCa, prostate cancer; t-PSA, total prostate-specific antigen; PHI, prostate health index; PCA3, prostate cancer associated 3.